A comprehensive, systematized search was conducted across EMBASE, Ovid MEDLINE, and Web of Science using terms related to “GLP-1 receptor agonists,” “type 2 diabetes mellitus,” and “hepatocellular carcinoma.” Eligible studies included adult populations (≥18 years) with T2DM prescribed GLP-1RAs and reported outcomes specific to HCC incidence or progression. Six studies met the inclusion criteria, and most demonstrated a significantly reduced risk of HCC among patients with T2DM treated with GLP-1RAs compared with those using insulin or sulfonylureas. Here, GLP1R is linked to hepatocellular carcinoma.